Sony Receives U.S. FDA Clearance for Operating Room Imaging Management Platform
With 510(k) clearance, platform streamlines OR and clinical access to imaging data
Sony Electronics' NUCLeUS(tm) Courtesy: Sony Electronics
By Whitney J. Palmer
Sony Electronics announced Wednesday that it received 510(k) clearance from the U.S. Food and Drug Administration for its NUCLeUS™ Operating Room, Imaging Management and Collaboration platform.
NUCLeUS is an open, vendor neutral video-over-IP platform that connects devices, applications, and data to facilitate surgical workflow. It connects to the PACS, hospital information system, operating room planning system, and DICOM worklists to, potentially, improve efficiency.
According to a company press release, NUCLeUS uses an existing network infrastructure to support up to 4K resolution and is designed to enhance and streamline workflow for operating rooms and clinical environments by providing direct imaging data access through a central dashboard. Via the system, providers can also capture and manage video and audio content in real-time.
“We are eager to put NUCLeUS in the hands of doctors, nurses, and OR managers in the [United States] so they can experience first-hand how the platform can dramatically improve surgical collaboration and potentially contribute to better outcomes,” said Theresa Alesso, president of Sony Electronics’ Pro divison in a press statement. “With the ongoing development of unique ‘smart applications,’ NUCLeUS will continue to push the boundaries of what is possible in the [operating room.]”
The system is already in use in more than 500 operating room venues in hospitals throughout Europe, including the United Kingdom, Belgium, and Sweden. Sales within the United States will begin immediately, according to the company.
Based on company information, important characteristics of NUCLeUS include:
- Secure hospital information system integration, fully HL7 and DICOM compliant
- Secure, encrypted methods to record, archive, distribute, and manage surgical video and other types of medical imaging and patient data without costly infrastructure upgrades
- Software-based platform that reduces room hardware requirements
- Fully scalable solution that can be extended to additional rooms or buildings
- Remote addition of smart applications and additional optional features upon release
- Support for third-party applications via APIs and other tools
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
